1 INTRODUCTION {#SEC1}
==============

Human cancers are characterized by the accumulation of somatic mutations, e.g. gross insertions and deletions, as well as the more subtle single base pair substitutions ([@btt182-B16]), some of which confer a growth advantage on the tumour cells ([@btt182-B15]). The Catalogue of Somatic Mutations in Cancer (COSMIC) ([@btt182-B3]) is an online repository of somatic mutation data, which includes amino acid substitutions (AASs). The identification of cancer-promoting AASs (driver mutations) promises to lead to a better understanding of the molecular mechanisms underlying the disease, as well as providing potential diagnostic and therapeutic markers ([@btt182-B11]). However, this remains a major challenge, as the majority of AASs detected in cancer genomes do not contribute to carcinogenesis; rather, these 'passenger mutations' are a consequence of tumorigenesis rather than a cause ([@btt182-B14]). Therefore, accurate automated computational prediction algorithms capable of distinguishing between driver and passenger mutations are of paramount importance.

A review by [@btt182-B30] describes the performance of several computational prediction algorithms ([@btt182-B1]; [@btt182-B4]; [@btt182-B5]; [@btt182-B6]; [@btt182-B7]; [@btt182-B20]; [@btt182-B23]; [@btt182-B22]; [@btt182-B24]; [@btt182-B29]) using a 'gold standard' validation benchmark ([@btt182-B26]). In our previous work, we developed the Functional Analysis through Hidden Markov Models (FATHMM) algorithm and, using a model weighted for inherited disease mutations, observed improved performance accuracies over alternative computational prediction methods using the same benchmark ([@btt182-B27]). However, the value of traditional computational prediction algorithms in cancer genomics remains unclear ([@btt182-B17]). For example, the shared characteristics between driver and other disease-causing mutations allow for a significant proportion of cancer-associated mutations to be identified (high-sensitivity/true positive rate); however, these methods are incapable of reliably distinguishing between driver and other disease-causing mutations. Furthermore, with respect to carcinogenesis, a large proportion of passenger mutations are still misclassified as having a role in tumour progression (low-specificity/true negative rate). As a result, several cancer-specific computational prediction algorithms capable of distinguishing between driver mutations and other germ line variants (both disease-causing and putatively neutral mutations) and/or capable of discriminating between somatic driver and passenger mutations have been developed ([@btt182-B9]; [@btt182-B12]; [@btt182-B18]; [@btt182-B25]).

In this work, we describe an adaptation to our original algorithm, which amalgamates sequence conservation within hidden Markov models (HMMs), representing the alignment of homologous sequences and conserved protein domains, with 'pathogenicity weights', representing the overall tolerance of the corresponding model to mutations ([@btt182-B27]), to potentiate the functional analysis of driver mutations. Using a model weighted for cancer-associated mutations, we observe performance accuracies, which outperform alternative computational prediction algorithms ([@btt182-B1]; [@btt182-B8]; [@btt182-B23]; [@btt182-B25]) when distinguishing between driver and other germ line mutations (both disease-causing and neutral polymorphisms). Furthermore, when discriminating between driver and passenger mutations (somatic), we observe performance accuracies comparable with other state-of-the-art computational prediction algorithms ([@btt182-B8]; [@btt182-B9]; [@btt182-B12]). A web-based implementation of our algorithm, including a high-throughput batch submission facility and a downloadable stand-alone package, is available at <http://fathmm.biocompute.org.uk>.

2 METHODS {#SEC2}
=========

2.1 The mutation datasets {#SEC2.1}
-------------------------

The mutation datasets used in this study were collected and assembled as follows: first, cancer-associated mutations (germ line and somatic) from the CanProVar database ([@btt182-B21]) (CanProVar---Version 54; <http://bioinfo.vanderbilt.edu/canprovar>) and putative neutral polymorphisms from the UniProt database ([@btt182-B2]) (UniProt---November 2011; <http://www.uniprot.org/docs/humsavar>) were downloaded and used to calculate our 'cancer-specific pathogenicity weights'. Next, we obtained three mutation datasets ([@btt182-B8]) and performed an independent benchmark comparing the performance of our algorithm with the performance of five alternative computational prediction algorithms ([@btt182-B1]; [@btt182-B8]; [@btt182-B23]; [@btt182-B25]). Finally, we obtained a published benchmark consisting of nine mutation datasets ([@btt182-B12]) and compared the performance of our algorithm with the performance of four alternative computational prediction algorithms ([@btt182-B1]; [@btt182-B12]; [@btt182-B23]; [@btt182-B25]). The composition of these datasets is summarized in [Table 1](#btt182-T1){ref-type="table"}, and the overlap between our training and benchmarking datasets is illustrated in [Supplementary Table S1](http://bioinformatics.oxfordjournals.org/lookup/suppl/doi:10.1093/bioinformatics/btt182/-/DC1). Table 1.Summary of mutation datasets used in this studyDatasetPositivesNegativesDescriptionTraining datasets    CanProVar12 720---A collection of cancer-associated mutations used to calculate our pathogenicity weights    UniProt---36 928A collection of putative neutral polymorphisms used to calculate our pathogenicity weightsCapriotti and Altman benchmark    CNO31633163Comprising driver mutations used to train the CHASM algorithm and neutral polymorphisms    CND31633163Comprising driver mutations used to train the CHASM algorithm and other germ line mutations (both disease-causing and neutral polymorphisms)    Synthetic31633163Comprising driver and passenger mutations (somatic) used to train the CHASM algorithmGonzalez-Perez *et al.* benchmark    COSMIC 2 + 1397839 850Comprising COSMIC mutations occurring in 2+ samples and COSMIC mutations occurring in one sample    COSMIC 5 + 1163139 850Comprising COSMIC mutations occurring in 5+ samples and COSMIC mutations occurring in one sample    COSMIC 2/POL39788040Comprising COSMIC mutations occurring in 2+ samples and neutral polymorphisms    COSMIC 5/POL16318040Comprising COSMIC mutations occurring in 5+ samples and neutral polymorphisms    COSMIC D/O215141 664Comprising driver mutations used to train the CHASM algorithm and COSMIC mutations not in the positive subset    COSMIC D/POL21518040Comprising driver mutations used to train the CHASM algorithm and neutral polymorphisms    COSMIC CGC/NONCGC486534 827Comprising COSMIC mutations falling within genes defined in the CGC and COSMIC mutations falling within genes outside the CGC    WG 2/179024 079Comprising somatic mutations occurring in 2+ samples and somatic mutations occurring in one sample    WG CGC/NONCGC130222 983Comprising somatic mutations falling within genes defined in the CGC and somatic mutations falling within genes outside the CGC[^2]

2.2 Scoring cancer-associated amino acid substitutions {#SEC2.2}
------------------------------------------------------

Following the procedure described in [@btt182-B27]: protein domain annotations from the SUPERFAMILY ([@btt182-B13]) (version 1.75) and Pfam ([@btt182-B28]) (Pfam-A and Pfam-B; version 26.0) databases are made. Next, the corresponding HMMs are extracted if the mutation maps onto a match state within the model, and the domain assignment is deemed to be significant (e-value ≤0.01). Where multiple HMMs are extracted, then the model with the largest information gain (as measured by the Kullback--Leibler divergence ([@btt182-B19]) from the SwissProt/TrEMBL amino acid composition) is used. Finally, we interrogate the amino acid probabilities within the model and assume that a reduction in the amino acid probabilities (when comparing the wild-type with the mutant residue) indicates a potential negative impact on protein function. Finally, the predicted magnitude of effect is weighted using cancer-specific pathogenicity weights ([Supplementary Methods](http://bioinformatics.oxfordjournals.org/lookup/suppl/doi:10.1093/bioinformatics/btt182/-/DC1)):

Here, *P~w~* and *P~m~* represent the underlying probabilities for the wild-type and mutant amino acid residues, respectively, and the pathogenicity weights, *W~c~* and *W~p~*, represent the relative frequencies of cancer-associated (CanProVar) and putative neutral polymorphisms (UniProt) mapping onto the relevant HMMs, respectively. A pseudo-count of 1.0 is incremented to our pathogenicity weights to avoid zero divisible terms.

2.3 Extending our algorithm to mutations falling outside conserved protein domains {#SEC2.3}
----------------------------------------------------------------------------------

The main disadvantage of our original algorithm was confining coverage (via the weighting scheme used) to protein missense variants falling within conserved protein domains. To increase coverage, we have developed an extension to the aforementioned data for predicting the functional effects of AASs falling outside conserved protein domains. In brief, *ab initio* HMMs, representing the alignment of homologous sequences within the SwissProt/TrEMBL database ([@btt182-B2]), are constructed using the *JackHMMER* component of HMMER3 ([@btt182-B10]) (one iteration with the optional---*hand* parameter applied). The predicted magnitude of effect is then calculated as in [Equation (1)](#btt182-M1){ref-type="disp-formula"}; however, these models are weighted with the relative frequencies of cancer-associated (CanProVar) and putative neutral polymorphisms (UniProt) mapping onto the top scoring sequence(s), and their homologous domain(s), being used to construct the model ([Supplementary Methods](http://bioinformatics.oxfordjournals.org/lookup/suppl/doi:10.1093/bioinformatics/btt182/-/DC1)).

2.4 Performance evaluation {#SEC2.4}
--------------------------

As recommended in [@btt182-B31], the performance of our method was assessed using the following six parameters \[[Equations (2--7)](#btt182-M2 btt182-M3 btt182-M4 btt182-M5 btt182-M6 btt182-M7){ref-type="disp-formula"}\]:

In the aforementioned data, *tp* and *fp* refer to the number of true positives and false positives reported and *tn* and *fn* denote the number of true negatives and false negatives reported.

3 RESULTS {#SEC3}
=========

3.1 A cancer-specific prediction threshold {#SEC3.1}
------------------------------------------

The [@btt182-B8] benchmark comprises three mutation datasets: the cancer and neutral only (CNO) mutation dataset assesses the performance of computational prediction algorithms when tasked with discriminating between driver mutations and neutral (germ line) polymorphisms; the cancer, neutral and other disease (CND) mutation dataset is used to evaluate the performance of computational prediction algorithms when tasked with distinguishing between cancer-associated and other germ line mutations (both disease-causing and neutral polymorphisms); and the synthetic mutation dataset measures the performance of computational prediction algorithms when differentiating between somatic driver and passenger mutations. Therefore, to derive a prediction threshold capable of being applied under all conditions, we plotted the distribution of the predicted magnitude of effect for all mutations in the Capriotti and Altman benchmark using a leave-one-out cross-validation procedure ([Fig. 1](#btt182-F1){ref-type="fig"}). From this, we calculated a prediction threshold at which the specificity and sensitivity of our algorithm were both maximized across the mutation datasets: −0.75. Using this threshold, we observed that a large proportion of driver mutations (92%) fell below our prediction threshold, whereas the vast majority of germ line polymorphisms (disease-causing/putative neutral mutations) and passenger mutations fell above our prediction threshold, 94 and 87%, respectively. Fig. 1.The distribution of the predicted magnitude of effect for all driver mutations against all non--cancer-associated (germ line and somatic) mutations in the [@btt182-B8] benchmark. Here, the dashed line represents our prediction threshold of −0.75 at which the specificity and sensitivity of our algorithm is maximized across all mutation datasets

3.2 An independent benchmark against other computational prediction algorithms {#SEC3.2}
------------------------------------------------------------------------------

Using the [@btt182-B8] mutation datasets, we performed an independent benchmark comparing the performance of our method with the performance of two generic computational prediction algorithms: SIFT ([@btt182-B23]) and PolyPhen-2 ([@btt182-B1]); alongside two cancer-specific computational prediction algorithms: Mutation Assessor ([@btt182-B25]) and SPF-Cancer ([@btt182-B8]). For this analysis, we obtained SIFT and PolyPhen-2 predictions using the corresponding algorithms' batch submission facilities, whereas Mutation Assessor predictions were collected using the available web service, and SPF-Cancer predictions were provided by the corresponding author on request (as no batch submission is available). The algorithm's default parameters and prediction thresholds were applied throughout our analysis.

First, using the cancer and neutral only (CNO) mutation dataset, we assessed the performance of these algorithms when tasked with distinguishing between driver mutations and putatively neutral polymorphisms. In addition, using the cancer, neutral and other disease (CND) mutation dataset, we assessed the performance of these algorithms when tasked with differentiating between driver mutations and other disease-causing mutations (non-neoplasm). From [Table 2](#btt182-T2){ref-type="table"}, and in terms of performance accuracies, it would seem that our method is the best-performing algorithm across these mutation datasets (94 and 93%, respectively). Using the synthetic mutation dataset, we assessed the performance of these algorithms when tasked with discriminating between somatic driver and passenger mutations. Here, our method outperforms SIFT, PolyPhen-2 and Mutation Assessor; it is comparable with SPF-Cancer (89 and 90%, respectively). Next, we compared the performance of our domain-based algorithm with the performance of our novel extension (capturing regions falling outside of conserved protein domains). We observed similar performances both within and outside conserved protein domains and concluded that our extension (and the corresponding weighting scheme) was just as effective as our domain-based algorithm when predicting the functional consequences of cancer-associated mutations ([Supplementary Table S2](http://bioinformatics.oxfordjournals.org/lookup/suppl/doi:10.1093/bioinformatics/btt182/-/DC1)). Finally, we plotted receiver operating characteristic (ROC) curves in the form of cumulative true positive/false positive plots centred on a conservative 1% error rate ([Fig. 2](#btt182-F2){ref-type="fig"}). These curves re-affirm the comparable performances between our algorithm and SPF-Cancer. In addition, these curves demonstrate the relatively poor performances of 'generic' computational prediction algorithms, such as SIFT and PolyPhen-2, when applied to predict the functional consequences of cancer-associated mutations. Fig. 2.ROC curves showing the cumulative true positive rate versus the cumulative false positive rate for the computational prediction algorithms evaluated in our independent benchmark Table 2.Performance of computational prediction methods using the Capriotti and Altman benchmarking datasetsMethodtpfptnfnAccuracy[^a^](#btt182-TF2){ref-type="table-fn"}Precision[^a^](#btt182-TF2){ref-type="table-fn"}Specificity[^a^](#btt182-TF2){ref-type="table-fn"}Sensitivity[^a^](#btt182-TF2){ref-type="table-fn"}NPV[^a^](#btt182-TF2){ref-type="table-fn"}MCC[^a^](#btt182-TF2){ref-type="table-fn"}Cancer and neutral only (CNO)    SIFT218056012669820.690.690.690.690.690.38    PolyPhen-2[^b^](#btt182-TF2){ref-type="table-fn"}2421124418946560.700.660.600.790.740.40    Mutation Assessor2403100421557510.720.710.680.760.740.45    SPF-Cancer287619629672870.920.940.940.910.910.85    FATHMM2858773077300**0.940.970.980.910.910.88**Cancer, neutral and other disease (CND)    SIFT21809437459820.570.550.440.690.590.14    PolyPhen-2[^b^](#btt182-TF2){ref-type="table-fn"}2421192112386560.560.540.340.790.620.14    Mutation Assessor2403192112387510.580.560.390.760.620.17    SPF-Cancer287641827452870.890.870.870.910.910.78    FATHMM28581612933300**0.930.950.950.910.910.85**Synthetic    SIFT2180143114349820.590.580.500.690.620.19    PolyPhen-2[^b^](#btt182-TF2){ref-type="table-fn"}242119029856560.560.540.340.790.620.14    Mutation Assessor2403147414327510.630.600.490.760.670.26    SPF-Cancer28592972866304**0.900.910.91**0.900.90**0.81**    FATHMM285836227103000.890.880.88**0.910.90**0.79[^3]

As our prediction threshold was derived using the same mutation datasets used in this benchmark (albeit using a leave-one-out analysis), and a large proportion of driver mutations is also present in our training data, we recognize the potential for bias in the observed performances. Therefore, to alleviate this bias, we further performed a 20-fold cross-validation procedure ([Supplementary Table S3](http://bioinformatics.oxfordjournals.org/lookup/suppl/doi:10.1093/bioinformatics/btt182/-/DC1)). We observed no significant deviations in the performance measures reported earlier in the text and, therefore, concluded that the performance of our algorithm is not an artefact of our weighting scheme.

Finally, to enable a direct (and fair) comparison between our algorithm and another leading computational prediction algorithm, CHASM ([@btt182-B9]), we performed the same 2-fold cross-validation procedure used in ([@btt182-B8]) using the synthetic dataset. Here, we observed an improved performance when using our algorithm ([Table 3](#btt182-T3){ref-type="table"}). Furthermore, we observed no significant deviations from our original performance measures reported earlier in the text. Table 3.A performance comparison using a 2-fold cross-validation procedureMethodAccuracyPrecisionSpecificitySensitivityNPVMCCCHASM0.800.850.870.730.760.60FATHMM**0.870.880.880.860.860.74**[^4] Table 4.Performance of computational prediction methods using the Gonzalez-Perez *et al.* benchmarking datasetsDatasetSIFTPolyPhen-2Mutation assessorTransFICFATHMMAcc.MCCAcc.MCCAcc.MCCAcc.MCCAcc.MCCThresholdCOSMIC 2 + 10.490.100.590.060.300.80**0.93**0.50**0.930.63**−3.50COSMIC 5 + 10.490.120.600.090.320.90**0.970.57**0.95**0.57**−3.50COSMIC 2/POL0.700.320.790.390.800.91**0.930.860.93**0.84−1.50COSMIC 5/POL0.710.320.860.410.710.96**0.98**0.760.97**0.89**−1.50COSMIC D/O0.480.090.610.100.180.780.880.25**0.900.35**−3.00COSMIC D/POL0.700.290.850.420.640.920.940.69**0.950.86**−0.75COSMIC CGC/NONCGC0.440.080.560.070.160.780.850.50**0.910.55**−1.60WG 2/10.840.020.710.010.100.890.960.23**0.970.31**−3.50WG CGC/NONCGC0.420.110.560.110.340.900.94**0.520.95**0.39−2.80[^5]

3.3 A performance comparison with a published review {#SEC3.3}
----------------------------------------------------

In addition to performing our own benchmark, we downloaded and used the [@btt182-B12] benchmark (comprising nine mutation datasets) to compare the performance of our algorithm with four alternative computational prediction algorithms: SIFT ([@btt182-B23]), PolyPhen-2 ([@btt182-B1]), Mutation Assessor ([@btt182-B25]) and TransFIC ([@btt182-B12]). For this analysis, we opted to compare our algorithm with the Mutation Assessor TransFIC, as it has been shown to outperform the SIFT TransFIC and PolyPhen-2 TransFIC. In accordance with ([@btt182-B12]), and to enable a fair comparison to be made between our algorithm and the Mutation Assessor TransFIC, we adjusted our prediction thresholds across the nine mutation datasets to maximize the Matthews correlation coefficient (MCC) of our algorithm. Here, our algorithm outperforms SIFT, PolyPhen-2 and Mutation Assessor across all mutation datasets. In addition, it seems our algorithm is comparable with the Mutation Assessor TransFIC ([Table 4](#btt182-T4){ref-type="table"}). The performance of our algorithm using our standard prediction threshold is documented in [Supplementary Table S4](http://bioinformatics.oxfordjournals.org/lookup/suppl/doi:10.1093/bioinformatics/btt182/-/DC1).

3.4 Benefits of a disease-specific weighting scheme {#SEC3.4}
---------------------------------------------------

To better understand the potential benefits of incorporating a cancer-specific weighting scheme into our algorithm, we compared the score/prediction assignments for all mutations in the [@btt182-B8] benchmark using a cancer-specific weighting scheme with the score/prediction assignments for the same mutations using our original inherited-disease weighting scheme. As expected, the odds of identifying driver and passenger mutations were 7.92 (CI: 6.82, 9.22) and 1.95 (CI: 1.69, 2.25) times greater, respectively, when using a cancer-specific weighting scheme. Furthermore, the odds of correctly identifying other disease-causing mutations as having no effect on tumour progression were 75.48 (CI: 59.70, 96.17) times greater when using a cancer-specific weighting scheme. The observed performance gain illustrates the ability of our algorithm to not only distinguish between driver and passenger mutations but also to discriminate between cancer-associated mutations and other germ line mutations (both disease-associated and neutral polymorphisms).

4 DISCUSSION {#SEC4}
============

In this article, we described an adaptation to the Functional Analysis through Hidden Markov Models (FATHMM) algorithm ([@btt182-B27]) in which a cancer-specific weighting scheme was incorporated to potentiate the functional analysis of driver mutations. The performance of our method was then benchmarked against four alternative computational prediction algorithms: SIFT ([@btt182-B23]) and PolyPhen-2 ([@btt182-B1]), Mutation Assessor ([@btt182-B25]) and SPF-Cancer ([@btt182-B8]); using the [@btt182-B8] benchmarking datasets. In terms of performance accuracies, FATHMM seems to be the best performing method available when assigned with the task of distinguishing between driver mutations and other germ line polymorphisms (both disease-causing and neutral). Furthermore, when tasked with discriminating between driver and passenger mutations (somatic), our method seems to perform as well as the alternative leading prediction algorithm: SPF-Cancer. Although the performance of our algorithm in this category does not represent an improvement over SPF-Cancer, our method offers a large-scale/high-throughput batch submission facility capable of analysing all foreseeable genomic/cancer datasets---an important facility that is not offered with SPF-Cancer. In addition, to facilitate a comparison between our algorithm and another leading computational prediction algorithm: CHASM ([@btt182-B9]), we performed a 2-fold cross-validation procedure and observed an improved performance when using our method. We also compared the performance of our algorithm with four computational prediction algorithms: SIFT ([@btt182-B23]), PolyPhen-2 ([@btt182-B1]), Mutation Assessor ([@btt182-B25]) and TransFIC ([@btt182-B12]), using a published benchmark ([@btt182-B12]). Once again, we observed improved performance accuracies over traditional computational prediction algorithms: SIFT, PolyPhen-2 and Mutation Assessor; and we noted comparable performances with the Mutation Assessor TransFIC.

In any fair comparison, care should be taken to reduce the potential overlap between the mutation datasets used for training and testing; however, this level of testing is not possible, as it would require obtaining and retraining each algorithm with common datasets. To remove the potential bias in our results, we performed a 20-fold cross-validation procedure across our benchmark. From this analysis, we observed no significant deviations in the performance of our algorithm and, therefore, concluded that the performances observed were not an artefact of the weighting scheme used.

The potential benefits of incorporating cancer-specific information into our predictions were assessed by comparing the performance of our cancer-specific weighting scheme with the performance of our original inherited-disease weighting scheme. In accordance with previous findings ([@btt182-B17]), we observed some similarities in driver scores/predictions between the two weighting schemes. However, we noted improved odds in identifying driver/passenger mutations using a cancer-specific weighting scheme. Unsurprisingly, we also noted significantly improved odds in correctly classifying disease-causing (non-neoplasm) mutations as having no effect on tumour progression. Therefore, by incorporating a cancer-specific weighting scheme, we have shown that our method is capable of identifying mutations that directly contribute to carcinogenesis, irrespective of other underlying disease associations.

To facilitate the analysis of large-scale cancer genomic datasets, our public web server (available at <http://fathmm.biocompute.org.uk>) provides unrestricted and near instant predictions for all possible amino acid substitutions within the human proteome. For example, we were capable of annotating the entire COSMIC ([@btt182-B3]) database---comprising of over half a million mutations---in \<1 h using a single processing core. In addition, we also provide an open-source software package allowing users to run our algorithm using their high-performance computing systems.
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